Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford BioDynamics ( (GB:OBD) ) just unveiled an update.
Oxford BioDynamics Plc announced that it will release its financial results for the year ending 30 September 2025 on 16 December 2025. This announcement highlights the company’s ongoing commitment to transparency and may impact its market positioning by providing stakeholders with insights into its financial health and operational progress.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics’ stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. These factors collectively suggest a high-risk investment with significant financial and operational challenges.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare through precision clinical diagnostic tests for life-changing diseases. The company offers products like the EpiSwitch® PSE and EpiSwitch® CiRT blood tests, which enhance the predictive accuracy of prostate cancer screening and immuno-oncology treatments, respectively. Their proprietary 3D genomic biomarker platform, EpiSwitch®, supports the development of these tests, with applications in oncology, neurology, inflammation, hepatology, and animal health. Headquartered in Oxford, UK, with operations in the US and Malaysia, OBD is listed on the London Stock Exchange’s AIM.
Average Trading Volume: 31,014,535
Technical Sentiment Signal: Strong Sell
Current Market Cap: £11.16M
See more insights into OBD stock on TipRanks’ Stock Analysis page.